T. Lahaye

TL;DR: Although the heterogeneous development of imatinib resistance is challenging, the fact that BCR-ABL is active in many resistant patients suggests that the chimeric oncoprotein remains a good therapeutic target.

TL;DR: In this paper, a real-time RT-PCR approach using fluorescent-labeled hybridization probes (LightCycler technology) was used to determine whether BCR-ABL transcript levels can predict chromosomal response.

TL;DR: The general recommendation of HSCT as first-line treatment option in chronic phase CML can no longer be maintained and should be replaced by a trial with modern drug treatment first.

TL;DR: The induction of MBN expression by IFN-α, but not imatinib, may contribute to the specific ability of IFn-α to induce an MBN- specific T-cell response in CML patients, which implies that the character of remissions achieved with either drug may not be equivalent and therefore a therapy modality combining IFN -α and imatin ib may be most effective.

TL;DR: It is concluded that treatment with imatinib in newly diagnosed CML patients is associated with a rapid decrease of BCR-ABL transcript levels, and nested PCR may reveal residual BCR/ABL transcripts in samples that are negative by real-time PCR.